Showing results (171-180 of 752) with videos related to
Sort By:
Pageof 76
Neurosurgery Clinics of North America|March 18, 2004
Intraventricular gliomasAaron S Dumont, Elana Farace, David Schiff, et al.Neuro-Oncology Advances|June 6, 2022
Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance)Evanthia Galanis, S Keith Anderson, Erin Twohy, et al.Neuro-Oncology|August 12, 2021
Management of venous thromboembolism in high-grade glioma: Does low molecular weight heparin increase intracranial bleeding risk?Jasmin Jo, Joseph Donahue, Guneet Sarai, et al.Neuro-Oncology Practice|January 20, 2023
Navigating disability insurance in the American healthcare system for the low-grade glioma patientLalanthica Yogendran, Mark Rudolf, Drew Yeannakis, et al.Idrugs : the Investigational Drugs Journal|February 4, 2010
XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLCYing Zhang, Fadila Guessous, Alex Kofman, et al.Neuro-Oncology Practice|May 15, 2023
Hepatotoxicity from high-dose methotrexate in primary central nervous system lymphomaJoy C Zhang, Matthew J Stotts, Bethany Horton, et al.Current Neurology and Neuroscience Reports|May 4, 2005
Targeted molecular therapy of malignant gliomasSantosh Kesari, Naren Ramakrishna, Claire Sauvageot, et al.Journal of Neuro-Oncology|April 27, 2022
Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patientsVasileios K Kavouridis, Keith L Ligon, Patrick Y Wen, et al.Current Opinion in Neurology|April 4, 2017
Immunomodulation for glioblastomaDavid A Reardon, Patrick Y Wen, Kai W Wucherpfennig, et al.Current Treatment Options in Neurology|March 10, 2015
How treatment monitoring is influencing treatment decisions in glioblastomasMartha R Neagu, Raymond Y Huang, David A Reardon, et al.Pageof 76